Uncategorized
PolyActiva Completes Recruitment in Key Phase I Glaucoma Implant Safety Study. Six-month Treatment Period Demonstrated.
CHICAGO--(BUSINESS WIRE)--PolyActiva Pty Ltd, a clinical-stage biotechnology company and leader in ocular drug delivery, has completed patient enrolment for its Phase I clinical trial to study safety and tolerability of its biodegradable, slow-release ocular implant for the treatment of glaucoma. PolyActiva’s implant has the potential to revolutionise the treatment for millions of glaucoma patients. Current glaucoma treatment requires eye drops to be administered daily, often multiple times eac